A Review of the Efficacy and Safety Profiles of the Novel Oral Anticoagulants in the Treatment and Prevention of Venous Thromboembolism

2018 ◽  
Vol 40 (12) ◽  
pp. 2140-2167 ◽  
Author(s):  
Alexis A. Coulis ◽  
William C. Mackey
Keyword(s):  
Venous Thromboembolism ◽  
Oral Anticoagulants ◽  
Novel Oral Anticoagulants ◽  
The Novel ◽  
Efficacy And Safety ◽  
Treatment And Prevention

The Novel Oral Anticoagulants for Acute Venous Thromboembolism: Is Warfarin Dead?

2017 ◽  
Vol 38 (01) ◽  
pp. 029-039 ◽  
Author(s):  
Serena Granziera ◽  
Nicola Veronese ◽  
Giacomo Zoppellaro ◽  
Alexander Cohen
Keyword(s):  
Venous Thromboembolism ◽  
Oral Anticoagulants ◽  
Novel Oral Anticoagulants ◽  
The Novel ◽  
Acute Venous Thromboembolism

scholarly journals Efficacy and safety of novel oral anticoagulants versus vitamin K antagonists in the treatment of venous thromboembolism

2018 ◽  
Vol 13 (3) ◽  
pp. 273
Author(s):  
Maodi Xu ◽  
Qingquan Xue ◽  
Zhichen Pu ◽  
Zijing Wu ◽  
Haitang Xie
Keyword(s):  
Venous Thromboembolism ◽  
Vitamin K ◽  
Meta Analysis ◽  
Vitamin K Antagonists ◽  
Oral Anticoagulants ◽  
New Oral Anticoagulants ◽  
Novel Oral Anticoagulants ◽  
Efficacy And Safety ◽  
Bleeding Events ◽  
The Difference

<p>The aim of this meta-analysis was to systematically evaluate the efficacy and safety of novel oral anticoagulants and vitamin K antagonists in the treatment of venous thromboembolism. A total of 6 studies met the inclusion criteria and a total of 19,350 patients with venous thromboembolism were included. Among them, rivaroxaban (3 RCTs, n=90/3,449/4,832); dabigatran (2 RCTs, n=200/2,539); edoxaban (1 RCT, n=8,240). The results of meta-analysis showed that the total bleeding rate after treatment with the vitamin K antagonist group was higher than with the new oral anticoagulant group (OR=0.82, 95% confidence interval 0.75-0.90, p&lt;0.0001), and the difference was highly statistically significant. Overall, new oral anticoagulants are compara-ble to vitamin K antagonists, but new oral anticoagulants can reduce the occurrence of bleeding events and the safety was superior to vitamin K antagonists.</p>

scholarly journals EFFICACY AND SAFETY OF THE NOVEL ORAL ANTICOAGULANTS COMPARED TO WARFARIN IN PATIENTS WITH NON VALVULAR ATRIAL FIBRILLATION

2016 ◽  
Vol 67 (13) ◽  
pp. 761
Author(s):  
Ilaria Gagliardi ◽  
Teresa Bruni ◽  
Elisa Rauseo ◽  
Vincenzo Paravati ◽  
Francesco Barilla ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Oral Anticoagulants ◽  
Novel Oral Anticoagulants ◽  
The Novel ◽  
Efficacy And Safety

scholarly journals Efficacy and Safety of the Novel Oral Anticoagulants in Atrial Fibrillation

Circulation ◽  
2012 ◽  
Vol 126 (20) ◽  
pp. 2381-2391 ◽  
Author(s):  
Francesco Dentali ◽  
Nicoletta Riva ◽  
Mark Crowther ◽  
Alexander G.G. Turpie ◽  
Gregory Y.H. Lip ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Oral Anticoagulants ◽  
Novel Oral Anticoagulants ◽  
The Novel ◽  
Efficacy And Safety
Sign in / Sign up

Export Citation Format

Share Document